Investor directory

Covis Pharma

Covis Pharma is a specialty pharmaceutical company that focuses on providing therapeutic solutions for patients with life-threatening and serious medical conditions. Founded in 2011 and headquartered in Zug, Switzerland, the company markets a range of branded and generic pharmaceuticals as well as injectables across various therapeutic areas, including cardiovascular, central nervous system, oncology, and acute care. Its product offerings include ceftazidime, cefuroxime, digoxin, tranylcypromine sulfate, and ranitidine hydrochloride injection. In addition to its existing product portfolio, Covis Pharma is engaged in developing new therapeutic solutions aimed at enhancing patients' quality of life in cardiology, psychiatry, neurology, oncology, and rheumatology. The company operates as a subsidiary of Covis Pharma Holdings.

Top Stages

Acquisition
https://www.covispharma.com
https://crunchbase.com/organization/covis-pharma-zug-switzerland
https://linkedin.com/company/covis-pharma-s�rl
https://pitchbook.com/profiles/company/53442-46

Jack Davis

CEO

Ozgur Kilic

Group CFO and COO

1 past transactions

AMAG Pharmaceuticals

Acquisition in 2020
AMAG Pharmaceuticals is a biopharmaceutical company, which utilizes the technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The Company manufactures and sells two approved products, Feraheme (ferumoxytol) Injection for intravenous (IV) and GastroMARK. On June 30, 2009, Feraheme was approved for marketing in the United States by the United States Food and Drug Administration (FDA), for use as an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.